Citations

Clear

3942 citation(s) found for "To, Van".

Regenerative Medicine Clinical Readiness
Yamada, Satsuki , Behfar, Atta , Terzic, André , Behfar, Atta , Terzic, Andre

Mayo Clinic

Regenerative Medicine | February 24, 2021 | Volume: 16 | Issue: 3 | Pages: 309-322

10.2217/rme-2020-0178 | PMID 33622049 Get It

Emerging Workforce Readiness in Regenerative Healthcare
Wyles, Saranya P. , Monie, Dileep D. , Paradise, Christopher R. , Meyer, Fredric B. , Hayden, Richard E. , Terzic, André , van Wijnen, Andre J , Terzic, Andre , Monie, Dileep D

Mayo Clinic

Regenerative Medicine | February 24, 2021 | Volume: 16 | Issue: 3 | Pages: 197-206

10.2217/rme-2020-0137 | PMID 33622054 Get It

Can we use intraoperative high‐frequency oscillations to guide tumor‐related epilepsy surgery?
Klink, Nicole van , Zweiphenning, Willemiek , Ferrier, Cyrille H., Gosselaar, Peter H., Miller, Kai J. , Braun, Kees P. J. , Zijlmans, Maeike , van Klink, Nicole E C , Zweiphenning, Willemiek J E M , Zijlmans, Maeike , Aronica, Eleonora

Mayo Clinic

Epilepsia | February 22, 2021 | Volume: 62 | Issue: 4 | Pages: 997-1004

10.1111/epi.16845 | PMID 33617688 Get It

AbstractObjectiveIn people with low‐grade intrinsic brain tumors, an epileptic focus is often located close to the lesion. High‐frequency oscillations (HFOs) in electrocorticography (ECoG) might help to delineate this focus. We investigated the relationship between HFOs and low‐grade brain tumors and their potential value for tumor‐related epilepsy surgery.MethodsWe analyzed pre‐ and postresection intraoperative ECoG in 41 patients with refractory epilepsy and a low‐grade lesion. Electrodes were designated as overlying the tumor, adjacent resected tissue (peritumoral), or outside the resection bed using magnetic resonance imaging (MRI) and intraoperative photographs. We then used a semiautomated approach to detect HFOs as either ripples (80–250 Hz) or fast ripples (250–500 Hz).ResultsThe rate of fast ripples was higher in electrodes covering tumor and peritumoral tissue than outside the resection (p = .04). Mesiotemporal tumors showed more ripples (p = .002), but not more fast ripples (p = .07), than superficial tumors. Rates of fast ripples were higher in glioma and extraventricular neurocytoma than in ganglioglioma or dysembryoplastic neuroepithelial tumor (DNET). The rate of ripples and fast ripples in postresection ECoG was not higher in patients with residual tumor tissue on MRI than those without. The rate of ripples in postresection ECoG was higher in patients with good than bad seizure outcome (p = .03). Fast ripples outside the resection and in post‐ECoG seem related to seizure recurrence.SignificanceFast ripples in intraoperative ECoG can be used to help guide resection in tumor‐related epilepsy surgery. Preresection fast ripples occur predominantly in epileptogenic tumor and peritumoral tissue. Fast ripple rates are higher in glioma and extraventricular neurocytoma than in ganglioglioma and DNET.
Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)
Kasper, Bernd , Achee, Annie, Schuster, Kathrin , Wilson, Roger , Oortmerssen, G. van , Gladdy, Rebecca A. , Hemming, Matthew L. , Huang, Paul H. , Jones, Robin L. , Sanfilippo, Roberta , Schuetze, Scott M. , Somaiah, Neeta , Tine, Brian A. Van , Okuno, Scott H. , Trent, Jonathan C. , Jones, Robin L , Van Tine, Brian A , Trent, Jonathan , Ingham, Matthew , Pollack, Seth M. , Reinke, Denise K. , Wilky, Breelyn A

Mayo Clinic

Cancers | February 21, 2021 | Volume: 13 | Issue: 4 | Pages: 886

10.3390/cancers13040886 | PMID 33672607 Get It

As leiomyosarcoma patients are challenged by the development of metastatic disease, effective systemic therapies are the cornerstone of outcome. However, the overall activity of the currently available conventional systemic treatments and the prognosis of patients with advanced or metastatic disease are still poor, making the treatment of this patient group challenging. Therefore, in a joint effort together with patient networks and organizations, namely Sarcoma Patients EuroNet (SPAEN), the international network of sarcoma patients organizations, and the National LeioMyoSarcoma Foundation (NLMSF) in the United States, we aim to summarize state-of-the-art treatments for leiomyosarcoma patients in order to identify knowledge gaps and current unmet needs, thereby guiding the community to design innovative clinical trials and basic research and close these research gaps. This position paper arose from a leiomyosarcoma research meeting in October 2020 hosted by the NLMSF and SPAEN.
The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment
Mrugała, Maciej M. , Pressley, Shelley M., Taylor, Jennie , Thomas, Alissa A. , Wefel, Jeffrey S. , Acquaye, Alvina , Haynes, Chas, Agnihotri, Sameer , Lim, Michael , Peters, Katherine B. , Sulman, Erik P. , Salcido, Joanne, Butowski, Nicholas , Hervey‐Jumper, Shawn L. , Mansouri, Alireza , Oliver, Kathy , Porter, Alyx B. , Nassiri, Farshad , Schiff, David , Dunbar, Erin, Hegi, Monika E. , Bent, Martin J. van den , Chang, Susan M. , Zadeh, Gelareh , Chheda, Milan G. , Wefel, Jeffrey S , Peters, Katherine B , Mansouri, Alireza , Armstrong, Terri S , van den Bent, Martin J , Zadeh, Gelareh , Chheda, Milan G , Sulman, Erik P , Ostrom, Quinn T. , Coven, Scott L. , Armstrong, Terri S. , Chang, Susan Marina

Mayo Clinic

Neuro-Oncology Advances | February 21, 2021 | Volume: 3 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdab035 | PMID 34007966 Get It

AbstractBackgroundIt remains unknown how the COVID-19 pandemic has changed neuro-oncology clinical practice, training, and research efforts.MethodsWe performed an international survey of practitioners, scientists, and trainees from 21 neuro-oncology organizations across 6 continents, April 24–May 17, 2020. We assessed clinical practice and research environments, institutional preparedness and support, and perceived impact on patients.ResultsOf 582 respondents, 258 (45%) were US-based and 314 (55%) international. Ninety-four percent of participants reported changes in their clinical practice. Ninety-five percent of respondents converted at least some practice to telemedicine. Ten percent of practitioners felt the need to see patients in person, specifically because of billing concerns and pressure from their institutions. Sixty-seven percent of practitioners suspended enrollment for at least one clinical trial, including 62% suspending phase III trial enrollments. More than 50% believed neuro-oncology patients were at increased risk for COVID-19. Seventy-one percent of clinicians feared for their own personal safety or that of their families, specifically because of their clinical duties; 20% had inadequate personal protective equipment. While 69% reported increased stress, 44% received no psychosocial support from their institutions. Thirty-seven percent had salary reductions and 63% of researchers temporarily closed their laboratories. However, the pandemic created positive changes in perceived patient satisfaction, communication quality, and technology use to deliver care and mediate interactions with other practitioners.ConclusionsThe pandemic has changed treatment schedules and limited investigational treatment options. Institutional lack of support created clinician and researcher anxiety. Communication with patients was satisfactory. We make recommendations to guide clinical and scientific infrastructure moving forward and address the personal challenges of providers and researchers.
Preface: promoting research in PLS: current knowledge and future challenges
Mitsumoto, Hiroshi , Conference, all Delegates of the PLS, Ajroud‐Driss, Senda , Andres, Patricia L., Andrews, Jinsy , Babu, Suma , Barohn, Richard J., Benatar, Michael, Chew, Sheena , Conwit, Robin , Davis, Frank, Drory, Vivian E., Elman, Lauren , Fernandes, J. Americo, Ferrey, Dominic, Finegan, Eoin, Fink, John K. , Floeter, Mary Kay, Fournier, Christina , Genge, Angela , Govindarajan, Raghav , Haase, Georg, Hardiman, Orla , Harms, Matthew B. , Hayat, Ghazala , Heiman‐Patterson, Terry , Hill, Bryan Alan, Hübers, Annemarie , Huey, Edward D. , Jawdat, Omar, Kano, Osamu , Kau, Kristen, Kiernan, Matthew C. , Kisanuki, Yasushi, Kurent, Jerome E., Kwan, Justin , Lange, Dale J. , Ludolph, Albert C. , Mackenzie, Ian R. , Manfredi, Giovanni , Marren, David, Family, and, Morita, Mitsuya , Murphy, Jennifer , Nations, Sharon , Oskarsson, Björn , Pellerin, David , Ravits, John , Rezania, Kourosh , Scelsa, Stephen N. , Siddique, Nailah, Simmons, Zachary , Statland, Jeffrey , Blitterswijk, Marka van , Berg, Leonard van den , Walk, David , Warden, Deborah L., Wymer, James , van Blitterswijk, Marka , Simmons, Zachary , Oskarsson, Björn , Hardiman, Orla , Kiernan, Matthew C , Walk, David , Turner, Martin R. , Conference, all Delegates of the PLS, Área-Gómez, Estela , Solano, Juan Marcos , Bede, Peter , Corcia, Philippe , Cudkowicz, Merit , Carvalho, Mamede A. de , Factor‐Litvak, Pam , Granit, Volkan , Family, and, Paganoni, Sabrina , Rouleau, Guy Armand , Siddique, Teepu , Silani, Vincenzo , Traynor, Bryan J.

Mayo Clinic

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | February 20, 2021 | Volume: 21 | Issue: sup1 | Pages: 1-2

10.1080/21678421.2020.1840795 | PMID 33602018 Get It

Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries
Hurson, Amber N. , Choudhury, Parichoy Pal , Gao, Chi , Eriksson, Mikael , Shi, Min , Jones, Michael E. , Evans, D. Gareth , Gaudet, Mia M. , Vachon, Celine M. , Easton, Douglas F. , García‐Closas, Montserrat , Chatterjee, Nilanjan , Group, for the B-CAST Risk Modelling, Simard, Jacques , Newman, William G. , Veen, Elke M. van , Harkness, Elaine F. , Chasman, Daniel I , Evans, D Gareth , Jones, Michael E , Newman, William G , García-Closas, Montserrat , Simard, Jacques , Eriksson, Mikael , Hüsing, Anika , Milne, Roger L. , Vachon, Celine M. , Chasman, Daniel I. , Schmidt, Marjanka K. , Kraft, Peter , Group, for the B-CAST Risk Modelling

Mayo Clinic

International Journal of Epidemiology | February 19, 2021 | Volume: 50 | Issue: 6 | Pages: 1897-1911

10.1093/ije/dyab036 | PMID 34999890 Get It

Abstract Background Rigorous evaluation of the calibration and discrimination of breast-cancer risk-prediction models in prospective cohorts is critical for applications under clinical guidelines. We comprehensively evaluated an integrated model incorporating classical risk factors and a 313-variant polygenic risk score (PRS) to predict breast-cancer risk. Methods Fifteen prospective cohorts from six countries with 239 340 women (7646 incident breast-cancer cases) of European ancestry aged 19–75 years were included. Calibration of 5-year risk was assessed by comparing expected and observed proportions of cases overall and within risk categories. Risk stratification for women of European ancestry aged 50–70 years in those countries was evaluated by the proportion of women and future cases crossing clinically relevant risk thresholds. Results Among women <50 years old, the median (range) expected-to-observed ratio for the integrated model across 15 cohorts was 0.9 (0.7–1.0) overall and 0.9 (0.7–1.4) at the highest-risk decile; among women ≥50 years old, these were 1.0 (0.7–1.3) and 1.2 (0.7–1.6), respectively. The proportion of women identified above a 3% 5-year risk threshold (used for recommending risk-reducing medications in the USA) ranged from 7.0% in Germany (∼841 000 of 12 million) to 17.7% in the USA (∼5.3 of 30 million). At this threshold, 14.7% of US women were reclassified by adding the PRS to classical risk factors, with identification of 12.2% of additional future cases. Conclusion Integrating a 313-variant PRS with classical risk factors can improve the identification of European-ancestry women at elevated risk who could benefit from targeted risk-reducing strategies under current clinical guidelines.
GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma
Dong, Zhiwei , Yeo, Kok Siong , Eggum, Erin N. Dankert , Rokita, Jo Lynne , Ung, Choong Yong , Levee, Taylor M., Her, Zuag Paj , Howe, Cassie J., Hou, Xiaonan , Ree, Janine H. van, Li, Shuai , He, Shuning , Fritchie, Karen , Torres‐Mora, Jorge , Lehman, Julia S. , Meves, Alexander , Razidlo, Gina L. , Rathi, Komal S. , Weroha, S. John , Look, A. Thomas , Deursen, Jan M. van , Zhu, Shizhen , Lopez, Gonzalo , Dankert Eggum, Erin N, Rokita, Jo Lynne , van Ree, Janine H, Tao, Ting , Torres-Mora, Jorge, Razidlo, Gina L , Look, A Thomas , Maris, John M , Zhu, Shizhen , Lehman, Julia S , Dankert, Erin N. , Zhang, Cheng , Tao, Ting , Li, Hu , Westendorf, Jennifer J. , Maris, John M.

Mayo Clinic

Cancer Research | February 18, 2021 | Volume: 81 | Issue: 11 | Pages: 2995-3007

10.1158/0008-5472.can-20-1890 | PMID 33602789 Get It

Abstract One of the greatest barriers to curative treatment of neuroblastoma is its frequent metastatic outgrowth prior to diagnosis, especially in cases driven by amplification of the MYCN oncogene. However, only a limited number of regulatory proteins that contribute to this complex MYCN-mediated process have been elucidated. Here we show that the growth arrest-specific 7 (GAS7) gene, located at chromosome band 17p13.1, is preferentially deleted in high-risk MYCN-driven neuroblastoma. GAS7 expression was also suppressed in MYCN-amplified neuroblastoma lacking 17p deletion. GAS7 deficiency led to accelerated metastasis in both zebrafish and mammalian models of neuroblastoma with overexpression or amplification of MYCN. Analysis of expression profiles and the ultrastructure of zebrafish neuroblastoma tumors with MYCN overexpression identified that GAS7 deficiency led to (i) downregulation of genes involved in cell–cell interaction, (ii) loss of contact among tumor cells as critical determinants of accelerated metastasis, and (iii) increased levels of MYCN protein. These results provide the first genetic evidence that GAS7 depletion is a critical early step in the cascade of events culminating in neuroblastoma metastasis in the context of MYCN overexpression. Significance: Heterozygous deletion or MYCN-mediated repression of GAS7 in neuroblastoma releases an important brake on tumor cell dispersion and migration to distant sites, providing a novel mechanism underlying tumor metastasis in MYCN-driven neuroblastoma. See related commentary by Menard, p. 2815
Assessment of kidney function: clinical indications for measured GFR
Ebert, Natalie , Bevc, Sebastjan , Bökenkamp, Arend , Gaillard, F. , Mariat, Christophe , Pálsson, Runólfur , Londen, Marco van , Schäeffner, Elke , Gaillard, Francois , Palsson, Runolfur , Schaeffner, Elke , Bökenkamp, Arend , van Londen, Marco , Ebert, Natalie , Hornum, Mads , Jager, Kitty J. , Eriksen, Björn O. , Rule, Andrew D. , White, Christine A.

Mayo Clinic

Clinical Kidney Journal | February 18, 2021 | Volume: 14 | Issue: 8 | Pages: 1861-1870

10.1093/ckj/sfab042 | PMID 34345408 Get It

Abstract In the vast majority of cases, glomerular filtration rate (GFR) is estimated using serum creatinine, which is highly influenced by age, sex, muscle mass, body composition, severe chronic illness and many other factors. This often leads to misclassification of patients or potentially puts patients at risk for inappropriate clinical decisions. Possible solutions are the use of cystatin C as an alternative endogenous marker or performing direct measurement of GFR using an exogenous marker such as iohexol. The purpose of this review is to highlight clinical scenarios and conditions such as extreme body composition, Black race, disagreement between creatinine- and cystatin C–based estimated GFR (eGFR), drug dosing, liver cirrhosis, advanced chronic kidney disease and the transition to kidney replacement therapy, non-kidney solid organ transplant recipients and living kidney donors where creatinine-based GFR estimation may be invalid. In contrast to the majority of literature on measured GFR (mGFR), this review does not include aspects of mGFR for research or public health settings but aims to reach practicing clinicians and raise their understanding of the substantial limitations of creatinine. While including cystatin C as a renal biomarker in GFR estimating equations has been shown to increase the accuracy of the GFR estimate, there are also limitations to eGFR based on cystatin C alone or the combination of creatinine and cystatin C in the clinical scenarios described above that can be overcome by measuring GFR with an exogenous marker. We acknowledge that mGFR is not readily available in many centres but hope that this review will highlight and promote the expansion of kidney function diagnostics using standardized mGFR procedures as an important milestone towards more accurate and personalized medicine.
Cell Surface Glycoprotein CD24 Marks Bone Marrow-Derived Human Mesenchymal Stem/Stromal Cells with Reduced Proliferative and Differentiation Capacity In Vitro
Peppel, Jeroen van de , Schaaf, Gerben , Matos, Adriana Arruda , Guo, Yuan , Strini, Tanja, Verschoor, W., Dudakovic, Amel , Wijnen, André J. van , Leeuwen, Johannes P.T.M. van , van Wijnen, Andre J

Mayo Clinic

Stem Cells and Development | February 17, 2021 | Volume: 30 | Issue: 6 | Pages: 325-336

10.1089/scd.2021.0027 | PMID 33593128 Get It